

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : H. Zaghouani) Group Art Unit 1644
 Appl. No. : 08/779,767)
 Filed : January 7, 1997) I hereby certify that this correspondence and all
 For : COMPOUNDS,) marked attachments are being deposited with
 COMPOSITIONS) the United States Postal Service as first-class
 METHODS FOR THE) mail in an envelope addressed to: Assistant
 ENDOCYTIC) Commissioner for Patents, Washington, D.C.
 PRESENTATION) 20231, on
 IMMUNOSUPPRESSIVE)
 FACTORS)
 Examiner : Patrick J. Nolan, Ph.D.)



I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

March 29, 2000

(Date)

Daniel Hart

Daniel Hart, Reg. No. 40,637

AMENDMENT AND RESPONSE TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed September 29, 1999 in the above-identified application, kindly amend the application as follows.

IN THE CLAIMS:

Please cancel Claim 5.

D
4. The composition of Claim 66 wherein said [peptide] T cell receptor antagonist derived from proteolipid protein is a peptide analog of [a peptide agonist wherein said peptide agonist is capable of activating a T cell response to] proteolipid protein.

Dz
9. The composition of Claim 66 wherein the composition comprises a fusion protein in which said protein fragment or peptide comprising a T cell receptor antagonist derived from proteolipid protein is covalently joined to said immunoglobulin or portion thereof.

P3
11. The composition of Claim 9 wherein the protein fragment or peptide comprising said T cell receptor antagonist derived from proteolipid protein is positioned within at least one